España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Hikma Pharmaceuticals
HKMPY
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Hikma Pharmaceuticals (HKMPY) Forecast
News
Earnings
Hikma Pharmaceuticals (HKMPY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Hikma Pharmaceuticals (OTC:HKMPY) Stock
Hikma Pharmaceuticals Stock (OTC: HKMPY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, September 06, 2024
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Vandana Singh
Wednesday, August 28, 2024
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Vandana Singh
Monday, June 12, 2023
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
Vandana Singh
Tuesday, March 31, 2020
Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa
Neer Varshney
Tuesday, December 10, 2019
Stocks That Hit 52-Week Highs On Tuesday
Lisa Levin
Thursday, April 06, 2017
UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma
Benzinga
Monday, March 20, 2017
Jazz Pharma Gives Shorts A Wake-Up Call After JZP-110 Study Results
Benzinga
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Benzinga
Wednesday, February 10, 2016
Hikma Pharmaceuticals Offering $535M Less than Earlier Offer to Acquire Boehringer Ingelheim's US Generic Drug Business
Benzinga
Wednesday, March 11, 2015
Hikma Pharmaceuticals 2014 Profit Surges
Benzinga
Wednesday, November 20, 2013
Hikma Signs Long Term Supply Agreement With Unilife To Enhance Delivery Of Generic Injectables
Benzinga
Wednesday, March 13, 2013
Hikma Pharma Full-Year Profit Rises 19%
Benzinga
